Research is being conducted on the use of STING agonists in cancer immunotherapy, with a focus on promoting tumor immune surveillance. The cGAS-STING signaling pathway is being explored as a potential target for cancer treatment, with various approaches being investigated, including the use of extracellular vesicles and nanovesicles. The development of STING agonists and their delivery methods, such as prodrug systems and inhalable nanovesicles, is an area of ongoing study in the field of cancer immunotherapy.